Drop in Zoom Meeting


The Next Meeting – Thursday 4th December 2025 at 7pm

Our drop-in Zoom chats provide a good opportunity for the newly diagnosed to meet seasoned travelers and discuss all things KC. Anyone interested in Keratoconus is free to join us.

Register to take part- Here

Please join us to discuss all things KC. We are totally open with no pre planned agenda. Ours is a truly bottom up organisation run by members, all of whom have KC or a close connection. There are no silly questions. If you are thinking it, then there is sure to be someone else with a similar idea.

We hope to see you then.

Sight Villiage – London

Sight Village London 2025 – NEW VENUE

Sight Village is the UK’s leading exhibition and an integral part of the blind and low-vision landscape, attracting thousands of visitors eager to explore the latest technology, products, and support services. It offers a unique opportunity to discuss and engage with new innovations in a sensory-rich environment, where you can see, touch, and fully experience products and services.

Sight Village is delighted to announce our New Venue for London 2025, which will be held at the: 

ILEC Conference Centre, on: Tuesday 18th & Wednesday 19th November 2025:

Tuesday: Doors open at 10.00am until 4.00pm

Wednesday: Doors open at 9.30am until 3.30pm.

Stop by and say Hello

For more details visit the Website

  • From West Brompton Station (approx. 5 minutes)
    • Exit the station and turn left onto Lillie Road.
    • Walk straight along Lillie Road.
    • The ILEC Conference Centre is on your left, connected to the Ibis London Earls Court Hotel.


Reflections from the Specialist Keratoconus & Scleral Lens Symposium, Hertford 2025

By Dr Sangeetha Rao

Author’s note:
Dr Sangeetha Rao, an Ophthalmologist and new member of the Keratoconus Self-Help and Support Group, shares her reflections from the 2025 Specialist Keratoconus & Scleral Lens Symposium in Hertford, a weekend of learning, collaboration, and connection.

As a new member of the Keratoconus Self-Help and Support Group, attending the Specialist Keratoconus & Scleral Lens Symposium in Hertford this October was both eye-opening and a lot of fun (yes, pun very much intended!). I wasn’t sure what to expect: a gathering of clinicians, researchers, and industry experts, all focused on improving care for people living with keratoconus. Would I feel out of place, or would I come away with insights that could truly make a difference?

A particular highlight was Peter’s presentation on behalf of the KC Self-Help and Support Group. Seeing the group’s principles articulated so clearly and watching clinicians and industry representatives respond was inspiring. It reinforced that supporting patients goes far beyond clinical care: emotional, social, and psychological support is just as vital as lenses themselves. Discussions extended to carers and relatives, the ageing KC population, and the crucial role of Eye Clinic Liaison Officers (ECLOs) in bridging communication between clinics and patients.

Of course, the hands-on sessions stole the show for me. I got to fit and remove scleral lenses and even take an eye impression, a fantastic insight into the skill and precision required. While the symposium was a deep dive into lenses, having our group present alongside clinicians and industry professionals reminded me that the journey is truly a collaborative one. Seeing everyone engage highlighted how shared experiences, guidance, and support can make all the difference in a patient’s journey, reinforcing the mantra: people first, lenses second.

Watching how small adjustments in edge clearance, peripheral curves, or fluid reservoirs can dramatically affect comfort and vision was fascinating. I now have an even deeper appreciation for the patience and dedication of both clinicians and patients managing these lenses day-to-day.

The programme covered a wide range of topics:

  • RGP and hybrid lenses, including “piggyback” systems and soft skirts to improve centration and reduce complications.
  • Mini and full scleral lenses, with guidance on achieving optimal central clearance, avoiding limbal compression, and managing common issues like impingement, blanching, decentration, or fogging.
  • Therapeutic applications, from ocular surface disease to post-surgical care and conditions such as SJS/TEN, showing that scleral lenses are not just about vision—they can protect, rehabilitate, and even act as a pre-surgical safety net.

Hearing directly from long-term scleral lens wearers reminded me that technology is only part of the picture. Comfort, confidence, and quality of life matter just as much, and every lens tells a story about the person behind it.

The symposium reinforced the value of collaboration between clinicians, patients, and support groups in delivering truly patient-centred care. Through shared experiences, guidance, and support, we help people navigate keratoconus, so it doesn’t have to be a lonely journey.

As an ophthalmologist, this experience deepened my understanding of complex lens fitting and the challenges faced by patients, but it also reminded me that empathy, communication, and advocacy are just as vital as clinical expertise. And yes, I had fun along the way. The hands-on sessions were thrilling, the learning intense, and the speakers brought great energy and humour to every session.

Overall, Hertford was a powerful reminder of the progress being made in keratoconus care, the importance of putting people first, lenses second, and the value of a supportive community. I left inspired, motivated, and excited to bring these lessons into practice and to continue advocating for the Keratoconus community every step of the way.

£2.4m funding to develop non-invasive treatment for keratoconus

University of Liverpool researchers receive £2.4 million to advance a minimally invasive treatment for keratoconus, aiming to improve patient access and reduce NHS costs

Researchers at the University of Liverpool have secured over £2.4 million in funding to develop a novel, non-invasive treatment for keratoconus, a progressive eye condition that causes the cornea to become misshapen, leading to significant vision impairment or blindness. This innovative approach uses a new cross-linking agent applied painlessly under local anaesthetic, without the need to remove the corneal epithelium, offering a safer and more accessible alternative to current invasive treatments.

The project, led by Professor Rachel Williams, aims to make this treatment available in community optometry practices, reducing the need for specialist hospital settings and potentially lowering the financial burden on the NHS, a promising development for the future of healthcare.

Keratoconus costs over £400m in the UK

Keratoconus affects one in 2,000 individuals in the UK, with prevalence rising to 1 in 200 among South Asian populations. The condition typically develops between the ages of 12 and 40, impacting education, employment, and quality of life. Figures from 2022 indicated that keratoconus cost the NHS over £400 million.

Current treatments prevent the disease progression; however, they are invasive and carry risks, including infections and long-term tissue damage.

Rachel Williams, Professor of Ophthalmic Bioengineering at the University of Liverpool, led the Liverpool research team, including Drs Lucy BosworthHelen CauldbeckAngela Stainthorpe, and Tansi Khodai, who will use Medical Research Council (MRC) funding to develop and clinically translate a new, minimally invasive treatment that offers a safer, more accessible alternative, a collaborative effort that includes the audience in the process.

Professor Williams said: “Our approach uses a novel cross-linking agent that can be administered painlessly under local anaesthetic, without removing the corneal epithelium – a key source of discomfort and complications in current treatments. This innovation has the potential to change the patient care pathway radically, making treatment available in community optometry practices rather than requiring specialist hospital settings.”

Over £2m funding for new treatment

Preclinical studies have already demonstrated the safety and efficacy of the novel cross-linking agent treatment in vivo, showing no histological changes in the cornea or surrounding tissues, providing reassurance about its potential benefits.

The new formulation is applied using a suction ring and does not require the removal of protective surface tissue, making the procedure more straightforward and more comfortable. As a result, the treatment could significantly reduce the financial burden on the NHS, potentially saving millions of pounds annually.

The team have been awarded £2,498,485 by the MRC Developmental Pathway, building on proof-of-concept work made possible through Harmonised IAA funding from the University’s Research, Partnerships and Innovation (RPI) directorate. Professor Williams has also benefited from ongoing support from the University’s Enterprise team, which has played a crucial role in facilitating collaborations and securing additional funding for the project.

Professor Williams concluded: “This award enables us to take the crucial next steps toward commercialising the treatment. We aim to partner with industry to bring this innovation into clinical use, working closely with our collaborator, Dr Vito Romano from the University of Brescia, reducing the need for invasive surgeries and dramatically improving access to care for patients with keratoconus.”

Read original article here.